ACT-GLOBAL Adaptive Platform Trial for Stroke
Recruiting now Phase 3 NCT06352632
Run by The George Institute · for 18 and older · All sexes
What this study is about
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.
Who can join (things the study team will check)
Platform Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of stroke Platform Exclusion Criteria: There are no platform level exclusion criteria Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.…
Where this trial is running
- The George Institute for Global Health, Sydney, New South Wales, Australia
- University of Calgary, Calgary, Alberta, Canada
Who to contact
Xiaoying Chen, PhD · +61280524549 · xchen@georgeinstitute.org.au
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06352632.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.